Phase 2 N=15 Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Cue-reactivity — 0.7; 1.1; 0.9; 2.4 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=153 Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents
Tourette Syndrome
Primary: Change From Baseline in the Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) at Week 12 — -9.87; -6.42 score on a scale — p==0.011
Phase 2 N=276 Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery
Postoperative Pain
Primary: Summed Pain Intensity Scores Collected Over 24 Hours — 92.60; 96.16 Units on a scale
Phase 2 N=7 Fenfluramine in CDKL5 Deficiency Disorder (CDD)
CDD
Primary: Change From Baseline in Median Monthly Convulsive Seizure Frequency — 88.429 Number of monthly seizures
Phase 2 N=127 Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Breast Cancer · HER2-negative Breast Cancer · HER2-positive Breast Cancer
Primary: Progression Free Survival — 95; 93 percentage of participants
Phase 2 N=241 Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines
Moderate to Severe Glabellar Frown Lines
Primary: Duration of Effect Defined as Time Between Treatment and Relapse to Baseline Status Assessed by the Investigator on the FWS — 175; 185; 210; 215 days — p== 0.881
Phase 2 N=91 Cognitive Enhancement Through Transcranial Laser Therapy
Healthy Participants · Mild Cognitive Impairment
Primary: Psychomotor Vigilance Task (PVT) — 341.89; 344.09; 331.11; 330.75 msec — p=0.79
Phase 2 N=127 A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
Relapsed or Refractory Solid Tumors
Primary: Objective Response Rate (ORR) At Week 16 Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO)…
Phase 2 N=463 Pilot Herniorrhaphy Study for Postoperative Analgesia
Postoperative Pain
Primary: Mean Summed Pain Intensity (SPI) Score — 83.71; 77.63; 95.24; 89.28 Units on a scale
Phase 2 N=430 Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy
Postoperative Pain · Bunions
Primary: Mean Summed Pain Intensity (SPI) Score Over 24 Hours — 69.16; 96.83; 83.38; 85.70 Units on a scale
Phase 2 N=20 A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.
Healthy
Primary: Median Fold Change of Cytokine Levels From Day 0 to Day 90 — 3254; 1.997; 16.83; -33.89 pg/mL
Phase 2 N=454 A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults
Healthy
Primary: Cohort 1: Geometric Mean Antibody Titers to Respiratory Syncytial Virus (RSV) Prefusion Conformation-stabilized F (preF) Protein Using preF Enzyme-linked Immunosorbent…
Phase 2 N=45 COMbination of Bipolar Androgen Therapy and Nivolumab
Castration-resistant Prostate Cancer · Metastatic Prostate Cancer · Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy + Nivolumab — 18 Participants
Phase 2 N=195 MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
Carcinoma · Metastatic Pancreatic Adenocarcinoma
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase — 7; 7; 3; 8…
Phase 2 N=175 Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
Leukemia, Myeloid, Acute
Primary: Phase I: Maximum Tolerated Dose (MTD) of Volasertib in Combination With LDAC (Schedule A) and Volasertib Monotherapy (Schedule B) — 350; 450 milligram (mg)